NCT04782271View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

December 21, 2021

Study Completion Date

December 21, 2021

Conditions
Safety, Tolerability and Pharmacokinetic Profile in Healthy VolunteersChoroidal Neovascularization
Interventions
DRUG

SYL18001 sodium Low dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium Middle dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium High dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium High dose b.i.d

1 drop in the randomized eye twice daily

Trial Locations (1)

28034

Sylentis Clinical Trial Site, Madrid

All Listed Sponsors
lead

Sylentis, S.A.

INDUSTRY

NCT04782271 - Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops | Biotech Hunter | Biotech Hunter